The Role of Innate Immunity in Graft-Versus-Host Disease and Complications following Allogeneic Stem Cell Transplant  by Holler, Ernst
From the
ical C
Financial d
Correspon
partm
tre, F
(e-ma
1083-8791
doi:10.101The Role of Innate Immunity in Graft-Versus-Host
Disease and Complications following Allogeneic
Stem Cell Transplant
Ernst HollerINTRODUCTION
The idea of an interface between bacterial patho-
gens and graft-versus-host disease (GVHD) was sug-
gested first by van Bekkum´s group [1] as early as
1974. They showed that mice grown under protective
environment for up to 100 days after bone marrow
transplantation (BMT) failed to develop GVHD [1].
Similar effects were seen when he used decontami-
nated versus contaminated subcutaneous F1 gut im-
plants as a target for GVHD [2]. Although the
effects were much weaker when he added spleen cells
as an additional T cell source, these studies demon-
strated an interaction between the intestinal flora
and activation of donor T lymphocytes. Crossreactiv-
ity between bacterial antigens and the H2 system was
postulated to explain this phenomenon. Clinical anal-
yses suggest an effect of decontamination on GVHD
only in selected subgroups of patients (e.g., SAA [3]),
that received allogeneic stem cell transplantation
(SCT).
With the description of cytokines as effectors of
GVHD and endotoxin/lipopolysaccharides (LPS) as
the central molecule resulting in activation of macro-
phages and antigen-presenting cells (APCs), the focus
shifted to the endotoxin-cytokine axis, which was most
activated in the presence of gastrointestinal damage in-
duced by pretransplant conditioning [4]. Ferrara and
Cooke [5] demonstrated LPS sensitivity as a major
determinant of GVHD, and neutralization of effector
molecules released by activated macrophages such as
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pulmonary damage [6].SPECIFIC RECEPTORSOF INNATE IMMUNITY
AND THE INFLAMMASOME
Until the description of the toll-like receptors
(TLRs), the world of endotoxin seemed to be rather
direct. Today, we have to deal with a large set of at
least 10 human TLRs, all of which have specific li-
gands. Stimulation of these receptors results in an or-
chestrated and receptor-specific response, and via
a complex cascade of intracellular pathways, in activa-
tion of pro-interleukin (IL)-1b and NFkB. Even
within the TLRs, some are expressed on the cell
membrane, whereas others are intracellular receptors
located in the cytoplasm. As outlined in the contribu-
tion of G. Nunez (Department of Pathology and
Comprehensive Cancer Center, The University of
Michigan Medical School, Ann Arbor, MI), there is
an even more complex system of exclusively intracellu-
lar cytoplasmatic receptors that result in activation of
the central cellular complex of inflammation, the in-
flammasome, allowing final processing of pro-IL1b
to IL1 via caspase 1 [7-9]. These nucleotide oligomer-
ization domain (NOD)-like receptors (NLR) have
gained substantial interest, as they represent an anti-
bacterial defense system highly preserved during evo-
lution, and the interaction of TLRs and NLRs is
essential to induce an orchestrated defense response
against bacteria [10]. Mutations and defects within
these receptors are associated with a variety of inflam-
matory diseases, such as Familiar Mediterrean Fever,
Muckle Wells Syndrome, or juvenile-onset sarcoidosis
[11]. More recently, the NLRNALP3 has been identi-
fied to be activated by urate crystals in gout, confirming
a central role for inflammasomes [12]. Given that in-
flammasomes are crucial for processing of IL1, another
important molecule in GVHD, it is likely that inflam-
masome-associate molecules might play a major role in
complications of allogeneic SCT, a notion strength-
ened by Granell et al. [13] demonstrating an associa-
tion between NALP2 and NALP3 polymorphisms
and prognosis of GVHD.59
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DAMAGED BARRIERS—LESSONS FROM
INFLAMMATORY BOWEL DISEASE
A large contribution to our modern understanding
of interaction of innate immunity and specific inflam-
mation came from the studies on pathophysiology and
genetic risk factors of inflammatory bowel disease,
especially Crohn’s disease (CD). As outlined in Ro-
gler´’s (Clinic for Gastroenterology and Hepatology,
Department of Internal Medicine, University Hospital
Zurich, Switzerland) presentation, the damaged intes-
tinal mucosal barrier and translocation of bacteria
result in a dysregulated intestinal immune response
that finally translates in the pathology of CD [14].
Many components of epithelial integrity and the intes-
tinal immune system have been described in the con-
text of these studies [15,16]. It is now clear that we
have several compartments of the intestinal immune
response with specific APCs in the epithelial layer
and the underlying lamina propria. Expression pat-
terns of TLRs and NLRs are different for these cells,
and activation of translocated bacteria versus tolerance
against commensals is regulated specifically and differ-
entially on these levels [17]. Furthermore, interaction
of NLR and TLR activation is likely to be centrally
involved in induction of regulatory T cells, which are
induced via activated APCs, maintain intestinal immu-
nologic homeostasis, and play a major role in intestinal
inflammation and GVHD [18]. It is also clear that the
compartmentalization of the immune response is valid
for all epithelial organs and is true for the bronchial
epithelial system as well as for the skin, where Langer-
hans cells and dermal dendritic cells have different
specific functions.GVHDAND DYSREGULATED EPITHELIAL
IMMUNE RESPONSE
Our interest in innate immunity was stimulated by
the observation that modulation of the intestinal flora
by lactobacilli resulted in an altered pathology of
experimental GVHD, which was accompanied by a
strong reduction of bacterial translocation across the
damage mucosa into the mesenteric lymph nodes
[19]. These studies suggested that the interaction of in-
testinal bacteria and components of the immune sys-
tem might occur at multiple levels. In line with this,
we and others subsequently were able to describe sin-
gle nucleotide polymorphisms (SNPs) in themuramyl-
depeptide receptor NOD2/CARD15 as a risk factor of
severeGVHD and treatment-relatedmortality (TRM)
[20-22]. More recently, we could extend this observa-
tion to pulmonary complications, as in a large series of
long-term patients NOD2/CARD15 SNPs signifi-
cantly associated with occurrence of bronchiolitisobliterans syndrome (BOS) [23]. The exact pathways
how these variants result in an altered inflammatory
response remains to be described. Both recipient epi-
thelial cells producing antibacterial molecules like de-
fensins in a NOD2/CARD15-dependent pathway [24]
and host- and donor-derived APCs and macrophages
are likely to be involved. The interleukin 23/TH17
pathway is likely to be involved, and might directly
link innate immune response and adaptive T cell re-
sponses, as IL23R SNPs were now identified as further
risk factors of both inflammatory bowel disease and
GVHD [25]. As shown [26], activation of APCs in
target organs of GVHD might initiate allogeneic
immune responses in target organs.
If these associations can be confirmed in ongoing
large prospective studies and functional consequences
of these associations can be elaborated, these observa-
tions should have substantial impact on our future
strategies: First, SNPs of innate immunity may help
to select either donors, patient-specific strategies, or
high-risk patients who needmore aggressive treatment
of GVHD. As an example, T cell depletion seemed to
be detrimental in patients and donors with NOD2/
CARD15 variants in 2 retrospective studies. Second,
modulation of the innate immune response at the
levels of epithelial inflammation using TLR and
NLR agonists or antagonists might help to interfere
with local activation of the allogeneic response.
Whereas systemic graft-versus-leukemia (GVL) effects
should be less affected.ACKNOWLEDGMENTS
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